The stock of Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has decreased by -6.15 when compared to last closing price of 610.86. Despite this, the company has experienced a -2.08% fall in its stock price over the last five trading sessions. zacks.com reported 2025-04-29 that The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Is It Worth Investing in Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Right Now?
The price-to-earnings ratio for Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is above average at 14.97x. The 36-month beta value for REGN is also noteworthy at 0.42. There are mixed opinions on the stock, with 14 analysts rating it as a “buy,” 7 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for REGN is 104.85M, and at present, short sellers hold a 2.48% of that float. The average trading volume of REGN on April 29, 2025 was 1.01M shares.
REGN’s Market Performance
REGN stock saw a decrease of -2.08% in the past week, with a monthly decline of -10.05% and a quarterly a decrease of -16.47%. The volatility ratio for the week is 2.97%, and the volatility levels for the last 30 days are 4.34% for Regeneron Pharmaceuticals, Inc (REGN). The simple moving average for the past 20 days is -1.12% for REGN’s stock, with a -32.31% simple moving average for the past 200 days.
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with Cantor Fitzgerald repeating the rating for REGN by listing it as a “Overweight.” The predicted price for REGN in the upcoming period, according to Cantor Fitzgerald is $695 based on the research report published on April 22, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see REGN reach a price target of $834, previously predicting the price at $762. The rating they have provided for REGN stocks is “Outperform” according to the report published on February 05th, 2025.
UBS gave a rating of “Neutral” to REGN, setting the target price at $738 in the report published on January 16th of the current year.
REGN Trading at -10.52% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.67% of loss for the given period.
Volatility was left at 4.34%, however, over the last 30 days, the volatility rate increased by 2.97%, as shares sank -10.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.45% lower at present.
During the last 5 trading sessions, REGN fell by -2.72%, which changed the moving average for the period of 200-days by -47.28% in comparison to the 20-day moving average, which settled at $579.63. In addition, Regeneron Pharmaceuticals, Inc saw -19.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
MARION E MCCOURT, the Officer of Regeneron Pharmaceuticals, Inc, proposed sale 1,000 shares at $844.61 during a trade that took place back on Nov 01 ’24, which means that MARION E MCCOURT is holding shares at $844,610 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.87 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.32. The total capital return value is set at 0.11. Equity return is now at value 15.95, with 12.43 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 126.81.
Currently, EBITDA for the company is 5.32 billion with net debt to EBITDA at -0.09. When we switch over and look at the enterprise to sales, we see a ratio of 4.29. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.73.
Conclusion
In summary, Regeneron Pharmaceuticals, Inc (REGN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
